Evaluation of the immunohistochemical scoring system of cdx2 expression as a prognostic biomarker in colon cancer

HIGHLIGHTS

• What: The authors conducted an immunohistochemical assessment of expression on a cohort of 43 intraoperatively obtained tumor specimens from patients diagnosed with colon cancer at Colt ea Clinical Hospital in Bucharest between April 2019 and December 2023. The authors aim to analyze this CDX2 expression diversity among different cancer clones within the same tumor, and to devise a new scoring system that encapsulates this intratumoral heterogeneity. The authors carefully outlined inclusion criteria to focus on cases of colon cancer where elective surgery was performed to remove the primary tumor, with no immunohistochemical assessment of CDX2 expression conducted . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.